LONDON (Reuters) - London-listed pharmaceutical group Shire said it was seeking to buy U.S. firm Baxalta in a $30 billion all-share deal to create a global specialist in medicines treating rare diseases with sales of $20 billion by 2020.
Reuters: Business News, Reuters: Business
Tue, 08/04/2015 - 4:54am
LONDON (Reuters) - London-listed pharmaceutical group Shire said it was seeking to buy U.S. firm Baxalta in a $30 billion all-share deal to create a global specialist in medicines treating rare diseases with sales of $20 billion by 2020.